



Imprimis Pharmaceuticals' Go Dropless™ Cataract Surgery Formulations to be Presented in Two Sessions at the 2014 American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium & Congress

April 22, 2014

SAN DIEGO, April 22, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, announced today its attendance and physicians' presentations at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium & Congress in Boston from April 25-29, 2014.

The American Society of Cataract and Refractive Surgery is an international educational society with more than 9,000 members. Its mission is to advance the art and science of ophthalmic surgery and the knowledge and skills of ophthalmic surgeons by providing clinical and practice management education and by working with patients, government, and the medical community to promote the delivery and advancement of high-quality eye care.

Details of the presentations of physician and patient experience with Imprimis' patent-pending compounded formulations at ASCRS include:

- Sunday, April 27, 2014, 1:00-2:30 p.m. EDT, "IVTA & Antibiotics," Jeffrey T. Liegner, Course 27-303: Better Surgery Through Chemicals: Topical and Intracameral Agents for the Anterior Segment Surgeon, Room 253B.
- Sunday, April 27, 2014, 3:33 p.m. EDT, "Intravitreal Placement of Antibiotic/Steroid as Substitute for Postoperative Drops After Cataract Surgery," M. Stewart Galloway, MD, Session: Intraocular Surgery - Medications, Room 152.

Additional information about Imprimis and the presentations will be available to conference attendees who visit the Imprimis booth (#1481).

Imprimis' proprietary patent-pending ophthalmic compounded formulations are now available with a physician's prescription in many states while the Company continues its Go Dropless™ campaign (<http://GoDropless.com/>). The campaign was created to inform ophthalmologists about dropless ophthalmic surgery opportunities and the unique injectable compounded drug formulations Imprimis has developed in conjunction with physicians and pharmacists.

ABOUT DROPLESS OPHTHALMIC SURGERY FORMULATIONS

Imprimis acquired the intellectual property for these patent-pending formulations in August of 2013. As the Company stated at that time, the current treatment regimen for the prevention of post-cataract surgery complications is a costly pre-operative and post-operative patient-administered eye drop regimen, which requires strict patient compliance and careful adherence to a prescribed dosing schedule. Individuals with physical limitations, impaired manual dexterity, or those who lack a supportive caregiver, are particularly vulnerable to non-compliance and the subsequent complications of untreated post-surgical issues. Imprimis' unique drug formulations utilize a fourth generation quinolone therapy combined with anti-inflammatory agent, providing new choices for physicians to address the primary ocular complications of ophthalmic surgery - risk of infection and post-operative inflammation.

ABOUT IMPRIMIS PHARMACEUTICALS

San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients at accessible prices. Imprimis is pioneering a new commercial pathway using compounding pharmacies for the formulation and distribution of its proprietary drug therapies which include formulations in ophthalmology, wound management and urology. For more information, please visit www.imprimispharma.com or www.GoDropless.com.

SAFE HARBOR

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its compounded formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; risks related to its compounding pharmacy operations; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and

raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

MEDIA CONTACT: Jen Carroll

jcarroll@imprimispharma.com

858.704.4587

SOURCE Imprimis Pharmaceuticals, Inc.